GlassScriptPhysician profile
Rowan Lindsay
NPI 1568906923
$5,532.09
in general payments reported to CMS, 2019-2025
23 companies · $4,586 in 2025
The $4,586 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $946 · 2025: $4,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,413 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,413.09 |
| Education | $119.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $845.98 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $626.54 | 2024-2025 | Austedo Xr, Uzedy |
| Alkermes, INC. | $619.24 | 2024-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $473.44 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $448.52 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $442.39 | 2024-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $397.37 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $357.97 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lundbeck LLC | $353.97 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Corium, LLC | $338.23 | 2024-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $107.54 | 2024-2025 | Trintellix |
| Almatica Pharma LLC | $101.18 | 2025 | Loreev Xr |
| Harmony Biosciences LLC | $48.26 | 2024-2025 | |
| Tris Pharma INC | $47.38 | 2024-2025 | Dyanavel Xr |
| Braeburn INC. | $43.61 | 2025 | Brixadi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $42.59 | 2025 | Erzofri Extended-Release |
| Axsome Therapeutics, INC. | $41.81 | 2024-2025 | Auvelity |
| Indivior INC. | $39.23 | 2025 | Sublocade |
| Biogen, INC. | $37.53 | 2024-2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $36.10 | 2025 | Qelbree |
| Bausch Health US, LLC | $35.65 | 2024-2025 | Aplenzin |
| Vertical Pharmaceuticals, LLC | $29.93 | 2024-2025 | Relexxii |
| Collegium Pharmaceutical, INC. | $17.63 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rowan Lindsay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.